New combo therapy aims to shrink advanced kidney tumors
NCT ID NCT06962787
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (BL-B01D1) combined with a standard targeted therapy (TKI), with or without an immunotherapy (pembrolizumab), in 260 adults with advanced kidney cancer that has spread. The goal is to see if these combinations shrink tumors and are safe. Participants must be 18-75, in good general health, and have a tumor sample available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET scan could reveal kidney cancer drug success in weeks, not months
- Kidney tumor ablation: does it destroy cancer and boost well-being?
- Blood test aims to spot hidden cancer cells in 9 tumor types
- New imaging registry aims to sharpen cancer treatment precision
- Personalized cancer vaccine shows promise in early trial
- Robot surgery showdown: single port vs multi port for cancer